Commencement of a phase II clinical trial of SG2000 in ovarian cancer
London, UK, and New York, NY,
London, UK, and New York, NY, September 15, 2010 - Spirogen Limited (the "Company") and Celtic Therapeutics Holdings LP ("Celtic Therapeutics") announced today the commencement of a Phase II clinical trial of SG2000 in ovarian cancer. The trial is being sponsored by the National Cancer Institute (NCI) of the USA, and is now actively recruiting patients for treatment.The open-label Phase II study will evaluate th…
read more »
Celtic Therapeutics to invest up to $15m in the development of Spirogen's cancer drug SG2000
London, UK,
Spirogen Limited (Spirogen), the UK-based developer of DNA-interactive drugs, today announced that the private equity firm Celtic Therapeutics Holdings LP will invest up to $15 million in the development of Spirogen’s lead cancer drug, SG2000. Spirogen expects to continue clinical development of SG2000 in an upcoming National Cancer Institute-sponsored multi-centre Phase II study of SG2000 in the USA in resistant and refractory ovarian c…
read more »
The Results of the Phase I Studies of SG2000 (SJG-136) to be Presented at ASCO, Chicago, June 2008
Abstract ID: 2504 Abstract Title: Final results of Phase I and pharmacokinetic trial of SJG-136 administered on a daily x 3 schedule. Session Type: Oral Presentation Role: Presenter Igor Puzanov Date: Monday, June 02, 2008 Time: 8:00AM - 11:00AM Presentation Time: 8:30AM - 8:45AM -- ENDS -- Centanamycin has dual activity against malaria by Scott Baltic Last Updated: 2008-03-17 17:13…
read more »
Paris (France) and London (United Kingdom)
Ipsen and Spirogen’s SJG-136 shows encouraging results in the treatment of refractory solid tumours at ASCO Ipsen (Euronext: IPN) and Spirogen Ltd. announced today that final results from a Phase I clinical trial of the DNA sequence recognizing minor groove binder SJG-136 sponsored by the US National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Ipsen were presented today at the American Socie…
read more »
Spirogen expands both Leadership and Management Team
London, UK,
Spirogen expands both Leadership and Management Team J. Barrie Ward accepts role as Chairman of the Board of Directors Christopher J Pugh accepts role as Chief Business Officer London, UK, 2006 - Spirogen Ltd announced the appointments of J. Barrie Ward as a Chairman of the Board of Directors and Christopher J Pugh as Chief Business Officer. Dr Ward brings a tremendous wealth of leadership skills and experiences to …
read more »